Dataset from A Randomized, Double-blind, Multi-center Study to Assess Safety and Tolerability of Different Oral Doses of BAY94-8862 in Subjects With Stable Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease Versus Placebo (Part A) or Versus Placebo and Spironolactone (Part B)
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00008548
下载链接
链接失效反馈官方服务：
资源简介：
A placebo (Part A) and placebo and active comparator controlled (Part B), double-blind and
randomized study to assess safety and tolerability of a new drug (BAY94-8862) given orally
创建时间：
2024-11-26
